Masato Shino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Masato Shino has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Katsumasa Takahashi
Department of Otorhinolaryngology, Takasaki General Medical Center
5 shared publications- Kazuaki Chikamatsu
Department of Otolaryngology-Head and Neck Surgery, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Gunma, Japan
5 shared publications Kazuaki Chikamatsu
Department of Otorhinolaryngology-Head & Neck Surgery, Gunma University School of Medicine
4 shared publications- Osamu Nikkuni
Department of Otorhinolaryngology-Head & Neck Surgery, Gunma University School of Medicine
4 shared publications Yoshihito Yasuoka
Department of Otolaryngology-Head & Neck Surgery, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan
4 shared publications- Yukihiro Takayasu
Department of Otorhinolaryngology-Head & Neck Surgery, Gunma University School of Medicine
4 shared publications
Latest Publications
- Open Access
- 6 October 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5905
The Efficacy of Radiotherapy without Surgery for External Auditory Canal Squamous Cell Carcinoma
External auditory canal (EAC) cancer is a rare disease for which there are no adequate evidence-based treatment strategies. Radiotherapy is often used as the initial treatment to preserve the organ. This study aimed to elucidate the efficacy of radiotherapy for EAC squamous cell carcinoma (SCC). Patients with T1 disease were treated with radiotherapy alone. Patients with T2–4 disease were treated with chemoradiotherapy. The median follow-up period was 30.4 months. The 3-year local control (LC) rate for all patients was 51%, the disease-free survival (DFS) rate was 44%, and the overall survival (OS) rate was 73%. For T1–3 disease, the 3-year LC rate was 74%, DFS was 62%, and OS was 89%. However, for T4 disease, the 3-year LC rate was 17%, DFS was 17%, and OS was 50%. In a univariate analysis, only the T-category was a significant factor for LC and DFS (p = 0.006 and 0.02, respectively). All local recurrences were within the high-dose irradiated area. The results of this study suggest chemoradiotherapy can be an alternative to a combination of surgery and postoperative radiation for T1–3 SCC of the EAC. However, the efficacy of chemoradiotherapy in T4 cases was inadequate.
- 6 October 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5905
Open AccessThe Efficacy of Radiotherapy without Surgery for External Auditory Canal Squamous Cell Carcinoma
External auditory canal (EAC) cancer is a rare disease for which there are no adequate evidence-based treatment strategies. Radiotherapy is often used as the initial treatment to preserve the organ. This study aimed to elucidate the efficacy of radiotherapy for EAC squamous cell carcinoma (SCC). Patients with T1 disease were treated with radiotherapy alone. Patients with T2–4 disease were treated with chemoradiotherapy. The median follow-up period was 30.4 months. The 3-year local control (LC) rate for all patients was 51%, the disease-free survival (DFS) rate was 44%, and the overall survival (OS) rate was 73%. For T1–3 disease, the 3-year LC rate was 74%, DFS was 62%, and OS was 89%. However, for T4 disease, the 3-year LC rate was 17%, DFS was 17%, and OS was 50%. In a univariate analysis, only the T-category was a significant factor for LC and DFS (p = 0.006 and 0.02, respectively). All local recurrences were within the high-dose irradiated area. The results of this study suggest chemoradiotherapy can be an alternative to a combination of surgery and postoperative radiation for T1–3 SCC of the EAC. However, the efficacy of chemoradiotherapy in T4 cases was inadequate.
- 20 October 2018
- Published by Oto-Rhino-Laryngological Society of Japan, Inc. in Nippon Jibiinkoka Gakkai Kaiho
- Vol. 121 (10) , 1288-1293
Validity of Treatment for Patients with Head and Neck Squamous Cell Carcinoma with Distant Metastasis Detected at the First Examination
- 20 October 2018
- Published by Oto-Rhino-Laryngological Society of Japan, Inc. in Nippon Jibiinkoka Gakkai Kaiho
- Vol. 121 (10) , 1288-1293
Validity of Treatment for Patients with Head and Neck Squamous Cell Carcinoma with Distant Metastasis Detected at the First Examination
- 1 January 2018
- Published by The Society of Practical Otolaryngology in Practica Oto-Rhino-Laryngologica
- Vol. 111 (9) , 656-657
Juvenile Laryngeal Papilloma
- 1 January 2018
- Published by The Society of Practical Otolaryngology in Practica Oto-Rhino-Laryngologica
- Vol. 111 (9) , 656-657
Juvenile Laryngeal Papilloma
- Open Access
- 20 February 2017
- Published by Springer Nature in Radiation Oncology
- Vol. 12 (1) , 39
Concurrent chemoradiotherapy with conventional fractionated radiotherapy and low-dose daily cisplatin plus weekly docetaxel for T2N0 glottic cancer
To assess the efficacy of concurrent chemoradiotherapy (CCRT) with daily low-dose cisplatin (CDDP) plus weekly docetaxel (DTX) for patients with T2N0 glottic cancer. Between January 2004 and December 2013, 62 treatment-naive patients with histologically proven T2N0 glottic cancer were treated with concurrent chemoradiotherapy. Radiation therapy (RT; 2 Gy daily fractions up to a total dose of 66 Gy) was administered in combination with daily low-dose CDDP (6 mg/m2, five times a week), plus weekly DTX (10 mg/m2) for up to 4 weeks from the commencement of RT. Median duration of follow-up was 70 months. The actuarial 3-year and 5-year overall survival rates were 95% and 93%. The 3-year and 5-year cause-specific survival rates were both 100%. The actuarial 3-year and 5-year local control rates were 94% and 94%, respectively. Hematologic toxicity (neutoropenia of severity ≥ Grade 3) was observed in 8% of the patients, and non-hematologic toxicity (radiation mucositis of severity ≥ Grade 3) developed in one patient (2%). Radiation dermatitis of severity ≥ Grade 3 and laryngeal necrosis developed in one patient. CCRT with weekly DTX and low-dose CDDP appears to be a practical and safe modality and is expected to improve local control. UMIN000025046 . Registered 1 October 2015, retrospectively registered.
- 20 February 2017
- Published by Springer Nature in Radiation Oncology
- Vol. 12 (1) , 39
Open AccessConcurrent chemoradiotherapy with conventional fractionated radiotherapy and low-dose daily cisplatin plus weekly docetaxel for T2N0 glottic cancer
To assess the efficacy of concurrent chemoradiotherapy (CCRT) with daily low-dose cisplatin (CDDP) plus weekly docetaxel (DTX) for patients with T2N0 glottic cancer. Between January 2004 and December 2013, 62 treatment-naive patients with histologically proven T2N0 glottic cancer were treated with concurrent chemoradiotherapy. Radiation therapy (RT; 2 Gy daily fractions up to a total dose of 66 Gy) was administered in combination with daily low-dose CDDP (6 mg/m2, five times a week), plus weekly DTX (10 mg/m2) for up to 4 weeks from the commencement of RT. Median duration of follow-up was 70 months. The actuarial 3-year and 5-year overall survival rates were 95% and 93%. The 3-year and 5-year cause-specific survival rates were both 100%. The actuarial 3-year and 5-year local control rates were 94% and 94%, respectively. Hematologic toxicity (neutoropenia of severity ≥ Grade 3) was observed in 8% of the patients, and non-hematologic toxicity (radiation mucositis of severity ≥ Grade 3) developed in one patient (2%). Radiation dermatitis of severity ≥ Grade 3 and laryngeal necrosis developed in one patient. CCRT with weekly DTX and low-dose CDDP appears to be a practical and safe modality and is expected to improve local control. UMIN000025046 . Registered 1 October 2015, retrospectively registered.
- 1 January 2017
- Published by Oto-Rhino-Laryngological Society of Japan, Inc. in Nippon Jibiinkoka Gakkai Kaiho
- Vol. 120 (12) , 1467-1472
Cetuximab-Induced Interstitial Pneumonia in Head and Neck Carcinoma
2013年から2016年の3年間にセツキシマブ (Cetuximab, Cmab) を投与した頭頸部癌88症例のうち, 7症例 (8.0%) が間質性肺炎を発症した. 有害事象グレード3以上の重症は4症例で, 3症例 (3.4%) が死亡した. Cmab 治療が奏効 (完全奏効または部分奏効) した43症例のうち, 間質性肺炎は7症例 (16.3%) に発症し, 5症例は導入化学療法後に Cmab 併用放射線照射で根治を目指したプロトコールであった. Cmab 治療効果が不変もしくは悪化の45症例では生じなかった (0%). 治療強度が高いプロトコール, 治療効果が高い症例ほど, 間質性肺炎に注意する必要がある.
- 1 January 2017
- Published by Oto-Rhino-Laryngological Society of Japan, Inc. in Nippon Jibiinkoka Gakkai Kaiho
- Vol. 120 (12) , 1467-1472
Cetuximab-Induced Interstitial Pneumonia in Head and Neck Carcinoma
2013年から2016年の3年間にセツキシマブ (Cetuximab, Cmab) を投与した頭頸部癌88症例のうち, 7症例 (8.0%) が間質性肺炎を発症した. 有害事象グレード3以上の重症は4症例で, 3症例 (3.4%) が死亡した. Cmab 治療が奏効 (完全奏効または部分奏効) した43症例のうち, 間質性肺炎は7症例 (16.3%) に発症し, 5症例は導入化学療法後に Cmab 併用放射線照射で根治を目指したプロトコールであった. Cmab 治療効果が不変もしくは悪化の45症例では生じなかった (0%). 治療強度が高いプロトコール, 治療効果が高い症例ほど, 間質性肺炎に注意する必要がある.
- 30 May 2015
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 21 (4) , 1175-1181
Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma
The aim of this study is to evaluate the clinicopathological significance of L-type amino acid transporter 1 (LAT1) expression in patients with advanced laryngeal squamous cell carcinoma (LSCC). A total of 73 patients with advanced LSCC were retrospectively reviewed. Tumor sections were stained by immunohistochemistry for LAT1, 4F2hc, system ASC amino acid transporter-2 (ASCT2), cell proliferation by Ki-67, microvessel density (MVD) determined by CD34 and p53. A positive LAT1, 4F2hc and ASCT2 expression (staining more than a quarter) in the primary sites were recognized in 85, 80 and 45 %, respectively, and a high LAT1, 4F2hc and ASCT2 expression (staining more than a half) yielded 48, 31 and 18 %, respectively. High expression of LAT1 was significantly associated with lymph node metastasis, 4F2hc, ASCT2, Ki-67 and p53. The expression of LAT1 was significantly correlated with ASCT2, 4F2hc, cell proliferation, and MVD. By univariate analysis, there was no statistically significant relationship between LAT1 expression and prognosis in advanced LSCC. LAT1, 4F2hc and ASCT2 were highly expressed in patients with advanced laryngeal cancer. Our study suggests that the expression of LAT1 plays a crucial role in the metastasis and tumor progression in advanced LSCC.
- 30 May 2015
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 21 (4) , 1175-1181
Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma
The aim of this study is to evaluate the clinicopathological significance of L-type amino acid transporter 1 (LAT1) expression in patients with advanced laryngeal squamous cell carcinoma (LSCC). A total of 73 patients with advanced LSCC were retrospectively reviewed. Tumor sections were stained by immunohistochemistry for LAT1, 4F2hc, system ASC amino acid transporter-2 (ASCT2), cell proliferation by Ki-67, microvessel density (MVD) determined by CD34 and p53. A positive LAT1, 4F2hc and ASCT2 expression (staining more than a quarter) in the primary sites were recognized in 85, 80 and 45 %, respectively, and a high LAT1, 4F2hc and ASCT2 expression (staining more than a half) yielded 48, 31 and 18 %, respectively. High expression of LAT1 was significantly associated with lymph node metastasis, 4F2hc, ASCT2, Ki-67 and p53. The expression of LAT1 was significantly correlated with ASCT2, 4F2hc, cell proliferation, and MVD. By univariate analysis, there was no statistically significant relationship between LAT1 expression and prognosis in advanced LSCC. LAT1, 4F2hc and ASCT2 were highly expressed in patients with advanced laryngeal cancer. Our study suggests that the expression of LAT1 plays a crucial role in the metastasis and tumor progression in advanced LSCC.
- Open Access
- 27 October 2014
- Published by Hindawi Limited in Case Reports in Otolaryngology
- Vol. 2014, 1-5
A Case of Pyriform Sinus Fistula Infection with Double Tracts
Pyriform sinus fistula is a rare clinical entity and the precise origin remains controversial. The fistula is discovered among patients with acute suppurative thyroiditis or deep neck infection of the left side of the neck and is usually located in the left pyriform sinus. To the best of our knowledge, only a single tract has been reported to be responsible for pyriform sinus fistula infection. We present a case of a 13-year-old female patient with a pyriform sinus fistula that caused a deep infection of the left side of the neck and showed double-tract involvement discovered during surgical resection of the entire fistula. Both tracts arose around the pyriform sinus and terminated at the upper portion of the left lobe of the thyroid.
- 27 October 2014
- Published by Hindawi Limited in Case Reports in Otolaryngology
- Vol. 2014, 1-5
Open AccessA Case of Pyriform Sinus Fistula Infection with Double Tracts
Pyriform sinus fistula is a rare clinical entity and the precise origin remains controversial. The fistula is discovered among patients with acute suppurative thyroiditis or deep neck infection of the left side of the neck and is usually located in the left pyriform sinus. To the best of our knowledge, only a single tract has been reported to be responsible for pyriform sinus fistula infection. We present a case of a 13-year-old female patient with a pyriform sinus fistula that caused a deep infection of the left side of the neck and showed double-tract involvement discovered during surgical resection of the entire fistula. Both tracts arose around the pyriform sinus and terminated at the upper portion of the left lobe of the thyroid.
- 21 March 2013
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 19 (4) , 649-656
Clinicopathological Significance of L-type Amino Acid Transporter 1 (LAT1) Expression in Patients with Adenoid Cystic Carcinoma
The expression of L-type amino acid transporter 1 (LAT1) is correlated with tumor cell growth and survival. However, the clinicopathological significance of LAT1 expression in adenoid cystic carcinoma (ACC) remains to be elucidated. The aim of this study is to investigate the clinicopathological significance of LAT1 expression in ACC. A total of 30 patients with ACC were retrospectively reviewed. Tumor sections were stained by immunohistochemistry for LAT1, p53, and CD98, and cell proliferation and microvessel density (MVD) were determined by Ki-67 and CD34, respectively. High LAT1 and CD98 expression were observed in 27 % (8/30) and 23 % (7/30) of samples, respectively (p > 0.999). The high expression of LAT1 was significantly correlated with cell proliferation (Ki-67) and the cell cycle regulator p53. By univariate analysis, solid histological pattern, maxillary tumor site, LAT1, CD98, Ki-67 and p53 were significantly associated with poor prognosis. Multivariate analysis demonstrated that the high expression of LAT1 was an independent prognostic factor for predicting poor prognosis after surgical resection. LAT1 is a promising clinical marker to predict the outcome after surgery in patients with ACC.
- 21 March 2013
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 19 (4) , 649-656
Clinicopathological Significance of L-type Amino Acid Transporter 1 (LAT1) Expression in Patients with Adenoid Cystic Carcinoma
The expression of L-type amino acid transporter 1 (LAT1) is correlated with tumor cell growth and survival. However, the clinicopathological significance of LAT1 expression in adenoid cystic carcinoma (ACC) remains to be elucidated. The aim of this study is to investigate the clinicopathological significance of LAT1 expression in ACC. A total of 30 patients with ACC were retrospectively reviewed. Tumor sections were stained by immunohistochemistry for LAT1, p53, and CD98, and cell proliferation and microvessel density (MVD) were determined by Ki-67 and CD34, respectively. High LAT1 and CD98 expression were observed in 27 % (8/30) and 23 % (7/30) of samples, respectively (p > 0.999). The high expression of LAT1 was significantly correlated with cell proliferation (Ki-67) and the cell cycle regulator p53. By univariate analysis, solid histological pattern, maxillary tumor site, LAT1, CD98, Ki-67 and p53 were significantly associated with poor prognosis. Multivariate analysis demonstrated that the high expression of LAT1 was an independent prognostic factor for predicting poor prognosis after surgical resection. LAT1 is a promising clinical marker to predict the outcome after surgery in patients with ACC.
- 15 October 2012
- Published by Wiley in The Laryngoscope
- Vol. 123 (2) , 440-445
Improvement of tracheal flap method for laryngotracheal separation
Objectives/Hypothesis: Recurrent pneumonia due to intractable aspiration is a life‐threatening disease. A tracheal flap method for children without previous tracheostomy has been previously reported. This study reports that improvements of this method and its three subtypes are widely applicable to patients with various conditions. Study Design: Surgical technique study. Methods: The tracheal flap method does not involve transection of the trachea but achieves laryngotracheal separation using the tracheal, mucoperichondrial, and sternohyoid muscle, along with anterior cervical skin flaps. This method can be divided into three subtypes as follows: A‐type, utilizing the tracheal flap (for patients without previous tracheostomy); B‐type, utilizing the mucoperichondrial and sternohyoid muscle flaps (for patients lacking an anterior tracheal wall); and C‐type, utilizing the esophageal flap (for patients with severe hypersalivation). In all three subtypes, the anterior cervical skin flap is employed. Results: The tracheal flap method was performed in 30 patients (24 children and six adults) at risk of developing intractable aspiration pneumonia. In all 30 cases, aspiration pneumonia was prevented without severe complications. No fistula formation was observed. Conclusions: All three subtypes (A‐, B‐, and C‐type) of the tracheal flap method are effective in preventing the recurrence of aspiration pneumonia. This method is applicable to diverse patient backgrounds regardless of age or previous tracheostomy. It is less invasive than Lindeman procedure. Furthermore, this method is acceptable to patients' families and improves the QOL of both patients and caregivers. Laryngoscope, 2012
- 15 October 2012
- Published by Wiley in The Laryngoscope
- Vol. 123 (2) , 440-445
Improvement of tracheal flap method for laryngotracheal separation
Objectives/Hypothesis: Recurrent pneumonia due to intractable aspiration is a life‐threatening disease. A tracheal flap method for children without previous tracheostomy has been previously reported. This study reports that improvements of this method and its three subtypes are widely applicable to patients with various conditions. Study Design: Surgical technique study. Methods: The tracheal flap method does not involve transection of the trachea but achieves laryngotracheal separation using the tracheal, mucoperichondrial, and sternohyoid muscle, along with anterior cervical skin flaps. This method can be divided into three subtypes as follows: A‐type, utilizing the tracheal flap (for patients without previous tracheostomy); B‐type, utilizing the mucoperichondrial and sternohyoid muscle flaps (for patients lacking an anterior tracheal wall); and C‐type, utilizing the esophageal flap (for patients with severe hypersalivation). In all three subtypes, the anterior cervical skin flap is employed. Results: The tracheal flap method was performed in 30 patients (24 children and six adults) at risk of developing intractable aspiration pneumonia. In all 30 cases, aspiration pneumonia was prevented without severe complications. No fistula formation was observed. Conclusions: All three subtypes (A‐, B‐, and C‐type) of the tracheal flap method are effective in preventing the recurrence of aspiration pneumonia. This method is applicable to diverse patient backgrounds regardless of age or previous tracheostomy. It is less invasive than Lindeman procedure. Furthermore, this method is acceptable to patients' families and improves the QOL of both patients and caregivers. Laryngoscope, 2012
- 1 November 2011
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 32 (6) , 624-626
Angiotensin II receptor blocker–induced angioedema in the oral floor and epiglottis
- 1 November 2011
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 32 (6) , 624-626
Angiotensin II receptor blocker–induced angioedema in the oral floor and epiglottis